高等学校化学学报 ›› 2010, Vol. 31 ›› Issue (10): 1987.

• 研究论文 • 上一篇    下一篇

17β-雌二醇对血管紧张素Ⅱ诱导的心功能抑制的保护作用及其机制

范艳艳1, 马瑶2, 张舵2, 付艳1   

  1. 1. 吉林大学第一医院妇产科,
    2. 整形外科, 长春 130021
  • 收稿日期:2010-01-06 出版日期:2010-10-10 发布日期:2010-10-10
  • 通讯作者: 付艳, 女, 博士, 教授, 博士生导师, 主要从事妇科肿瘤及妇科内分泌研究. E-mail: f_y@jlu.edu.cn

Protective Effect and Mechanism of 17β-Estradiol for the Induced-inhibition on Cardiac Function by Angiotensin Ⅱ

FAN Yan-Yan1, MA Yao2, ZHANG Duo2, FU Yan1*   

  1. 1. Department of Obstetrics and Gynecology,
    2. Department of Plastic Surgery, First Hospital, Jilin University, Changchun 130021, China
  • Received:2010-01-06 Online:2010-10-10 Published:2010-10-10
  • Contact: FU Yan. E-mail: f_y@jlu.edu.cn

摘要: 为探讨17β-雌二醇(E2)对血管紧张素Ⅱ(AngⅡ)诱导的心功能抑制的保护作用及其可能的机制, 应用Langendorff 灌流装置, 将含有AngⅡ, E2+AngⅡ及E2+ICI(182)+AngⅡ的灌流液灌注于离体大鼠心脏, 比较心脏收缩功能参数; 以差速贴壁法分离并培养乳鼠心肌细胞, 用AngⅡ, AngⅡ+E2及AngⅡ+E2+ICI182分别刺激心肌细胞, 以MTT法比较各组心肌细胞的增殖情况, 并用Western Blotting方法检测p-p38水平. 结果表明, 雌激素可以改善AngⅡ诱导的心脏收缩舒张功能障碍, 抑制AngⅡ诱导的心肌细胞的增殖, 其调控机制可能与其干预p38MAPK信号通路的活化有关, 雌激素的作用部分是通过其特异性受体实现的.

关键词: 17β-雌二醇, 血管紧张素Ⅱ, 心脏收缩, 心肌细胞, 丝裂原活化蛋白激酶

Abstract: In order to investigate the protective effect and mechanism of 17β-estradiol for the induced-inhibition on cardiac function by angiotensin Ⅱ, Langendorff perfusion apparatus was used to inject perfusion fluid with AngⅡ, E2+AngⅡ, and E2+ICI+AngⅡ into in vitro hearts of mice, where the results were recorded and the cardiac systolic parameters were compared. Differential adhesion was applied to isolate and cultivate cardiomyocytes of mastomys mice, while these cells were respectively stimulated by AngⅡ, AngⅡ+E2, and AngⅡ+E2+ICI. The proliferative statuses of these groups of cardiomyocytes were compared by MTT method and the levels of p-p38 were measured by Western Blotting. In comparison to the control group, the perfusion of AngⅡ reduced the cardiac systole and diastole, where the ratio of dP/dt and the LVDP was significantly inhibited. When compared to the control group(non-stimulated), the values of these groups were respectively reduced by 21.3%, 37.1%, and 24%(P<0.05). Application of 100 nmol/L E2 could significantly improve the reduced cardiac functions by AngⅡ. When compared to the group with AngⅡ, the LVDP and the ratio of dP/dt in the pre-perfusion group with 100 nmol/L E2 were increased by 9.4%, 40.8%, and 22.4%(P<0.05). When specific E2-receptor inhibitor, 1 μmol/L ICI182, was added along with protection by 100 nmol/L E2, it was found that the application of ICI182 could partially block the protective effect of E2. In comparison to the control group, cardiomyocytes in the group with stimulation by 100 nmol/L AngⅡ significantly showed increase[A value: (0.37±0.08) vs. (0.25±0.09), P<0.05]. And, the pre-treatment with 10 nmol/L E2 could inhibit the induced proliferation of cardiomyocytes by AngⅡ[A value: (0.27±0.02) vs. (0.37±0.08), P<0.05]. In addition, ICI182 could partially block off the anti-AngⅡ-induced proliferative effect on cardiomyocytes by E2. By comparing to the blank control group, the level of p-p38 in the stimulant group with 100 nmol/L AngⅡ greatly increased[(0.26±0.06) vs. (0.12±0.05), P<0.05]. The pre-treatment with 10 nmol/L E2 could inhibit the elevation in level of p-p38, as induced by AngⅡ[(0.13±0.07) vs. (0.26±0.06), P<0.05], while ICI182 had no significant effect to inhibit E2. Estrogen could improve the AngⅡ-induced dysfunction in cardiac systole and diastole, as well as preventing proliferation of cardiomyocytes by AngⅡ. The regulatory mechanism might involve the interference on the activation of p38-MAPK signal transduction pathway. The effect of Estrogen was partially achieved by its specific receptors.

Key words: 17β-Estradiol, Angiotensin Ⅱ, Systole, Cardiomyocytes, MAPK

TrendMD: